Insight, China's Pharmaceutical Industry

Company Medical Device

Roche Launches Liver Disease Panel – Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced the launch of its Liver Disease Panel,...

Company Drug

AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy

Fineline Cube May 28, 2026

AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug...

Company Drug

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

Fineline Cube May 28, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that Australia’s Therapeutic Goods Administration (TGA) has...

Company Drug

Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery

Fineline Cube May 28, 2026

Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has...

Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with...

Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a strategic partnership with BeOne...

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from...

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced...

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a...

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Fineline Cube May 27, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received separate clinical...

Company

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Fineline Cube May 27, 2026

Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive...

Company

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Fineline Cube May 27, 2026

The Global Medical Device Training, Exhibition, Trading and Innovation Center was officially inaugurated this week...

Company Drug

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Drug

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...

Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026

Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...

Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026

Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics...

Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026

Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Roche Launches Liver Disease Panel – Digital Algorithms Combine Biomarker Diagnostics with CE-Certified LiverPRO to Transform Chronic Liver Disease Management

AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm – First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy

InnoCare Pharma Secures Australian TGA Approval for Hibruka in Relapsed/Refractory Mantle Cell Lymphoma – Highly Selective BTK Inhibitor Expands International Footprint

Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

You Missed

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally